Skip Navigation



Mol. Hum. Reprod. Advance Access published online on September 10, 2004

Molecular Human Reproduction, doi:10.1093/molehr/gah110
© 2004 by Oxford University Press
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
10/11/793    most recent
gah110v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Muttukrishna, S.
Right arrow Articles by Jauniaux, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muttukrishna, S.
Right arrow Articles by Jauniaux, E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received August 19, 2004
Accepted August 20, 2004

Article

Inhibin, activin, follistatin, activin receptors and {beta}-glycan gene expression in the villous tissue of miscarriage patients

S. Muttukrishna 1*, C. Bearfield 1, J. Johns 1, and E. Jauniaux 1

1 Department of Obstetrics and Gynaecology, Royal Free University College Medical School, 86-96 Chenies Mews, London WC1E 6HX, UK

* To whom correspondence should be addressed. E-mail: s.muttukrishna{at}ucl.ac.uk.


   Abstract

Maternal circulating levels of inhibin A are significantly lower in patients with clinical symptoms of miscarriage. The objective of this study was to quantify relative expression of inhibin {alpha}, inhibin/activin {beta}A, {beta}B, {beta}C, follistatin, activin receptors and {beta}-glycan genes and content of inhibin A, activin A and follistatin protein in villous tissue of first trimester miscarriages and gestation-matched normal pregnancies. Twelve women with clinical symptoms of miscarriage were matched with 12 normal pregnancies for gestational age. Total RNA was isolated from placental samples. Complementary DNA produced by reverse transcription was used in the real-time PCR to quantify the expression of the genes. The ratio between the target and rRNA 18S was calculated to provide relative gene expression. Villous tissue homogenates were used for the determination of the content of inhibin A, activin A and follistatin protein. Maternal serum was assayed for inhibin A, activin A and follistatin. All villous samples expressed inhibin {alpha}, inhibin/activin {beta}A, {beta}B, {beta}C, follistatin, activin receptors (ACTRIA, ACTRIB, ACTRIIA, ACTRIIB) and {beta}-glycan genes. There was no significant difference in the relative expression of these genes between the groups. Villous content of inhibin A, activin A and follistatin were also not different between the two groups. Maternal serum levels of inhibin A were significantly lower in the miscarriage group compared to the controls. The decreased maternal levels of inhibin A in miscarriage patients could be due to a decrease in placental mass prior to embryonic demise. This finding also confirms that the trophoblast is the major source of inhibin A after the luteo-placental shift in early pregnancy.

Keywords: activin; activin receptors; {beta}-glycan; follistatin; inhibin.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
ReproductionHome page
R. L Jones, C. Stoikos, J. K Findlay, and L. A Salamonsen
TGF-{beta} superfamily expression and actions in the endometrium and placenta.
Reproduction, August 1, 2006; 132(2): 217 - 232.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.